Tags

Type your tag names separated by a space and hit enter

New L-dopa codrugs as potential antiparkinson agents.
Arch Pharm (Weinheim). 2008 Jul; 341(7):412-7.AP

Abstract

This paper reports the synthesis and preliminary evaluation of new L-dopa (LD) conjugates (1 and 2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds 1 and 2 was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the rat. Rat striatal concentration of LD and dopamine (DA), and central nervous effects were evaluated after oral administration of the codrugs 1 and 2. The results suggest that, though our codrugs are devoid of significant antioxidant activity, they are able to induce sustained delivery of DA in rat striatum and can improve LD and DA release in the brain.

Authors+Show Affiliations

Dipartimento di Scienze del Farmaco, Università G D'Annunzio, Chieti, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18581391

Citation

Sozio, Piera, et al. "New L-dopa Codrugs as Potential Antiparkinson Agents." Archiv Der Pharmazie, vol. 341, no. 7, 2008, pp. 412-7.
Sozio P, Iannitelli A, Cerasa LS, et al. New L-dopa codrugs as potential antiparkinson agents. Arch Pharm (Weinheim). 2008;341(7):412-7.
Sozio, P., Iannitelli, A., Cerasa, L. S., Cacciatore, I., Cornacchia, C., Giorgioni, G., Ricciutelli, M., Nasuti, C., Cantalamessa, F., & Di Stefano, A. (2008). New L-dopa codrugs as potential antiparkinson agents. Archiv Der Pharmazie, 341(7), 412-7. https://doi.org/10.1002/ardp.200700228
Sozio P, et al. New L-dopa Codrugs as Potential Antiparkinson Agents. Arch Pharm (Weinheim). 2008;341(7):412-7. PubMed PMID: 18581391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New L-dopa codrugs as potential antiparkinson agents. AU - Sozio,Piera, AU - Iannitelli,Antonio, AU - Cerasa,Laura Serafina, AU - Cacciatore,Ivana, AU - Cornacchia,Catia, AU - Giorgioni,Gianfabio, AU - Ricciutelli,Massimo, AU - Nasuti,Cinzia, AU - Cantalamessa,Franco, AU - Di Stefano,Antonio, PY - 2008/6/27/pubmed PY - 2008/9/26/medline PY - 2008/6/27/entrez SP - 412 EP - 7 JF - Archiv der Pharmazie JO - Arch Pharm (Weinheim) VL - 341 IS - 7 N2 - This paper reports the synthesis and preliminary evaluation of new L-dopa (LD) conjugates (1 and 2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds 1 and 2 was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the rat. Rat striatal concentration of LD and dopamine (DA), and central nervous effects were evaluated after oral administration of the codrugs 1 and 2. The results suggest that, though our codrugs are devoid of significant antioxidant activity, they are able to induce sustained delivery of DA in rat striatum and can improve LD and DA release in the brain. SN - 0365-6233 UR - https://www.unboundmedicine.com/medline/citation/18581391/New_L_dopa_codrugs_as_potential_antiparkinson_agents_ L2 - https://doi.org/10.1002/ardp.200700228 DB - PRIME DP - Unbound Medicine ER -